newsfilter
← Latest News
Business Wire·

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small